Endotoxin activity trend and multi-organ dysfunction in critically ill patients with septic shock, who received Polymyxin-B hemadsorption: A multicenter, prospective, observational study.
ICU
critical care
endotoxin
polymyxin‐b hemadsorption
sepsis
septic shock
Journal
Artificial organs
ISSN: 1525-1594
Titre abrégé: Artif Organs
Pays: United States
ID NLM: 7802778
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
revised:
20
03
2023
received:
02
01
2023
accepted:
06
04
2023
medline:
29
9
2023
pubmed:
28
9
2023
entrez:
28
9
2023
Statut:
ppublish
Résumé
The baseline endotoxin activity (EA Subgroup analysis of the prospective, multicenter, observational study EUPHAS2. We included 50 critically ill patients with septic shock and EA Septic shock was mainly caused by 27 abdominal (54%) and 17 pulmonary (34%) infections, predominantly due to Gram negative bacteria (39 patients, 78%). The SAPS II score was 67.5 [52.8-82.3] and predicted a mortality rate of 75%. Between T In critically ill patients with septic shock and EA
Sections du résumé
BACKGROUND
BACKGROUND
The baseline endotoxin activity (EA
METHODS
METHODS
Subgroup analysis of the prospective, multicenter, observational study EUPHAS2. We included 50 critically ill patients with septic shock and EA
RESULTS
RESULTS
Septic shock was mainly caused by 27 abdominal (54%) and 17 pulmonary (34%) infections, predominantly due to Gram negative bacteria (39 patients, 78%). The SAPS II score was 67.5 [52.8-82.3] and predicted a mortality rate of 75%. Between T
CONCLUSIONS
CONCLUSIONS
In critically ill patients with septic shock and EA
Substances chimiques
Polymyxin B
J2VZ07J96K
Endotoxins
0
Types de publication
Observational Study
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1361-1370Subventions
Organisme : ESTOR
Organisme : Toray Industries
Investigateurs
Salvatore Lucio Cutuli
(SL)
Silvia De Rosa
(S)
Ricard Ferrer
(R)
Juan Carlos Ruiz-Rodriguez
(JC)
Adolf Ruiz-Sanmartin
(A)
Laura Cascarano
(L)
Edoardo Forin
(E)
Vinicio Danzi
(V)
Monica Zanella
(M)
Francesco Forfori
(F)
Claudio Ronco
(C)
Massimo Antonelli
(M)
Informations de copyright
© 2023 International Center for Artificial Organ and Transplantation (ICAOT) and Wiley Periodicals LLC.
Références
Rudd K, Johnson S, Agesa K, Shackelford K, Tsoi D, Kievlan D, et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the global burden of disease study. Lancet. 2020;395:200–11.
Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith C, French C, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021;47:1181–247.
Singer M, Deutschman C, Seymour C, Shankar‐Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis‐3). JAMA. 2016;315:801–10.
Seymour C, Gesten F, Prescott H, Friedrich M, Iwashyna T, Phillips G, et al. Time to treatment and mortality during mandated emergency Care for Sepsis. N Engl J Med. 2017;376:2235–44.
Cutuli S, Carelli S, Grieco D, De Pascale G. Immune modulation in critically ill septic patients. Medicina (Kaunas). 2021;57:552.
Cutuli S, Grieco D, De Pascale G, Antonelli M. Hemadsorption. Curr Opin Anaesthesiol. 2021;34:113–8.
Vincent J, Sakr Y, Singer M, Martin‐Loeches I, Machado F, Marshall J, et al. Prevalence and outcomes of infection among patients in intensive care units in 2017. Jama. 2020;323:1478–87.
Park B, Lee J. Recognition of lipopolysaccharide pattern by TLR4 complexes. Exp Mol Med. 2013;45:e66.
Kellum J, Foster D, Walker P. Endotoxemic shock: a molecular phenotype in sepsis. Nephron. 2023;147:17–20.
Romaschin A, Harris D, Ribeiro M, Paice J, Foster D, Walker P, et al. A rapid assay of endotoxin in whole blood using autologous neutrophil dependent chemiluminescence. J Immunol Methods. 1998;212:169–85.
Klein D, Derzko A, Foster D, Seely A, Brunet F, Romaschin A, et al. Daily variation in endotoxin levels is associated with increased organ failure in critically ill patients. Shock. 2007;28:524–9.
Marshall J, Foster D, Vincent J, Cook D, Cohen J, Dellinger R, et al. Diagnostic and prognostic implications of endotoxemia in critical illness: results of the MEDIC study. J Infect Dis. 2004;190:527–34.
Cruz D, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. Jama. 2009;301:2445–52.
Payen D, Guilhot J, Launey Y, Lukaszewicz A, Kaaki M, Veber B, et al. Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial. Intensive Care Med. 2015;41:975–84.
Dellinger R, Bagshaw S, Antonelli M, Foster D, Klein D, Marshall J, et al. Effect of targeted polymyxin B hemoperfusion on 28‐day mortality in patients with septic shock and elevated endotoxin level: the EUPHRATES randomized clinical trial. Jama. 2018;320:1455–63.
Klein D, Foster D, Walker P, Bagshaw S, Mekonnen H, Antonelli M. Polymyxin B hemoperfusion in endotoxemic septic shock patients without extreme endotoxemia: a post hoc analysis of the EUPHRATES trial. Intensive Care Med. 2018;44:2205–12.
The early use of polymyxin b hemoperfusion in the abdominal sepsis 2.
Early Use of Polymyxin B Hemoperfusion in the Abdominal Sepsis 2 Collaborative Group. Polymyxin B hemoperfusion in clinical practice: the picture from an unbound collaborative registry. Blood Purif. 2014;37:22–5.
Cutuli S, Artigas A, Fumagalli R, Monti G, Ranieri V, Ronco C, et al. Polymyxin‐B hemoperfusion in septic patients: analysis of a multicenter registry. Ann Intensive Care. 2016;6:77.
Ev E, Altman D, Egger M, Pocock S, Gøtzsche P, Vandenbroucke J, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studie. Lancet. 2007;370:1453–7.
Le Gall J, Lemeshow S, Saulnier F. A new simplified acute physiology score (SAPS II) based on a European/north American multicenter study. Jama. 1993;270:2957–63.
Wagner D, Draper E. Acute physiology and chronic health evaluation (APACHE II) and Medicare reimbursement. Health Care Financ Rev. 1984;Suppl:91–105.
Rhodes A, Evans L, Alhazzani W, Levy M, Antonelli M, Ferrer R, et al. Surviving sepsis campaign: international guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017;43:304–77.
Vincent J, Moreno R, Takala J, Willatts S, Mendonça AD, Bruining H, et al. The SOFA (sepsis‐related organ failure assessment) score to describe organ dysfunction/failure. On behalf of the working group on sepsis‐related problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22:707–10.
Bellomo R, Ronco C, Kellum J, Mehta R, Palevsky P, the ADQI workgroup. Acute renal failure – definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004;8:R204–R12.
KDIGO AKI Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;17:1–138.
Chawla L, Bellomo R, Bihorac A, Goldstein S, Siew E, Bagshaw S, et al. Acute kidney disease and renal recovery: consensus report of the acute disease quality initiative (ADQI) 16 workgroup. Nat Rev Nephrol. 2017;13:241–57.
Ronco C, Klein D. Polymyxin B hemoperfusion: a mechanistic perspective. Crit Care. 2014;18:309.
Forfori F, Brogi E, Sidoti A, Giraudini M, Monti G, Zarrillo N, et al. Regional citrate‐calcium anticoagulation during polymyxin‐B hemoperfusion: a case series. Int J Artif Organs. 2018;41:319–24.
Fujii T, Ganeko R, Kataoka Y, Furukawa T, Featherstone R, Doi K, et al. Polymyxin B‐immobilized hemoperfusion and mortality in critically ill adult patients with sepsis/septic shock: a systematic review with meta‐analysis and trial sequential analysis. Intensive Care Med 2018;44:167–78, 178.
Romaschin A, Obiezu‐Forster C, Shoji H, Klein D. Novel insights into the direct removal of endotoxin by polymyxin B hemoperfusion. Blood Purif. 2017;44:193–7.
De Rosa S, Cutuli S, Ferrer R, Antonelli M, Ronco C, COVID‐19 EUPHAS2 Collaborative Group. Polymyxin B hemoperfusion in coronavirus disease 2019 Patients with endotoxic shock: case series from EUPHAS2 registry. Artif Organs. 2021;45:E187–E94.
Bellomo R, Kellum J, Ronco C, Wald R, Martensson J, Maiden M, et al. Acute kidney injury in sepsis. Intensive Care Med. 2017;43:816–28.
Fujimori K, Tarasawa K, Fushimi K. Effectiveness of polymyxin B hemoperfusion for sepsis depends on the baseline SOFA score: a nationwide observational study. Ann Intensive Care. 2021;11:141.
Ruiz‐Rodriguez J, Plata‐Menchaca E, Chiscano‐Camón L, Ruiz‐Sanmartin A, Pérez‐Carrasco M, Palmada C, et al. Precision medicine in sepsis and septic shock: from omics to clinical tools. World J Crit Care Med. 2022;11:1–21.
Ruiz‐Rodríguez J, Plata‐Menchaca E, Chiscano‐Camón L, Ruiz‐Sanmartin A, Ferrer R. Blood purification in sepsis and COVID‐19: what's new in cytokine and endotoxin hemoadsorption. J Anesth Analg Crit Care. 2022;2:15.
De Rosa S, Villa G, Ronco C. The golden hour of polymyxin B hemoperfusion in endotoxic shock: the basis for sequential extracorporeal therapy in sepsis. Artif Organs. 2020;44:184–6.
De Rosa S, Samoni S, Ronco C. Sequential extracorporeal therapy collaborative device and timely support for endotoxic, septic, and cardiac shock: a case report. Blood Purif. 2020;49:502–8.
De Rosa S, Cutuli S, Lorenzin A, Zanella M. Sequential extracorporeal therapy in sepsis. Contrib Nephrol. 2022.
Srisawat N, Tungsanga S, Lumlertgul N, Komaenthammasophon C, Peerapornratana S, Thamrongsat N, et al. The effect of polymyxin B hemoperfusion on modulation of human leukocyte antigen DR in severe sepsis patients. Crit Care. 2018;22:279.
Morris A, Datta D, Shankar‐Hari M, Stephen J, Weir C, Rennie J, et al. Cell‐surface signatures of immune dysfunction risk‐stratify critically ill patients: INFECT study. Intensive Care Med. 2018;44:627–35.
Iba T, Klein D. The wind changed direction and the big river still flows: from EUPHRATES to TIGRIS. J Intensive Care. 2019;7:7.
Lee W, Kim H, Kim E. Impact of polymyxin B hemoperfusion therapy on high endotoxin activity level patients after successful infection source control: a prospective cohort study. Sci Rep. 2021;11:24132.
Kim J, Park Y, Moon K, Park J, Jeong Y, Kim E. Polymyxin B hemoperfusion as a feasible therapy after source control in abdominal septic shock. World J Gastrointest Surg. 2019;11:422–32.
Payen D. The gut as a hidden source of sepsis. Minerva Anestesiol. 2020;86:662–9.